Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. ​

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

<p><span>The most innovative startup in health and life sciences in Europe at BioFit, 2020</span></p>

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.
READ MORE

Latest News

2026-06-16 00:00:00

StemSight granted patent in Singapore

StemSight has been granted a patent in Singapore, and received a notice of patent allowance in Canada and Japan. With the first patent now granted for the novel product, StemSight is entering an important growth phase as we prepare for Series A financing and future clinical development. Read the full press release here.

2026-04-13 00:00:00

New CheckOrphan article featuring StemSight

Our Chief Commercial Officer Ross Macdonald shares insights in a recent CheckOrphan interview on how StemSight's technology aims to cure limbal stem cell deficiency. Read the full piece to learn more about the future of regenerative eye therapies.

2026-06-08 00:00:00

StemSight pitching in Berlin

StemSight has been selected to pitch at the GeneNovate pitch day in Berlin on June 9. The event brings together science-driven startups in the field of cell and gene therapies. StemSight will also be participating in the bio:cap biotech and AI investment festival on June 9 -11 as part of the Pfizer startup area. Our CEO Laura Koivusalo will be presenting StemSight in Berlin in both events, meeting investors and potential partners.

2026-04-24 00:00:00

Life Science Daily News article

A newly published article by CEO Laura Koivusalo in Life Science Daily News explores the rapid progress of iPSC technology and the field’s next major challenges. It highlights what it will take to translate promising innovations into broader, real-world use. Read the full article to gain deeper insights into the topic.

More News

Want to know more?

Interested to join our next investment round? Want to hear about our latest developments? Just thought of someone we absolutely need to meet?

Send us a message!

CONTACT US

Subscribe to our newsletter

Subscribe now

Supported by:

Co-funded by: